Forxiga
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 9887712.
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Astrazeneca Pharmaceuticals (Pty) Ltd | Forxiga | 5, 10 | 460214, 460215 | Not determined | PI |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Forxiga 5 EACH TABLET CONTAINS DAPAGLIFLOZIN PROPRANEDIOL 5,0 mg | 5Film-coated tablets | 46021446/21.2/0214Approved 12 February 2026 | Registered | Not determined | PI |
| Forxiga 10 EACH TABLET CONTAINS DAPAGLIFLOZIN PROPRANEDIOL 10,0 mg | 10Film-coated tablets | 46021546/21.2/0215Approved 12 February 2026 | Registered | Not determined | PI |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.